Seagen is the biotech sector’s leading developer of antibody-drug conjugates, which deliver cell-killing toxins to diseased cells by attaching them to an antibody that seeks out proteins on tumor cells. Its first, Adcetris, is on track to become a blockbuster this year as a treatment of various types of lymphoma.
Protein degradation is a relatively new research area in biotech, with companies like Nurix, Kymera Therapeutics and C4 Therapeutics going public in 2020 and others like Seed Therapeutics and Lycia Therapeutics winning partnerships with Eli Lilly.
